FDA authorizes blood purification device to treat COVID-19
The Food and Drug Administration today issued an emergency use authorization for a pair of blood purification systems to treat adult COVID-19 patients admitted to the intensive care unit with severe respiratory illness. The authorized devices filter patients’ blood to remove excess proteins that can cause respiratory or organ failure. The EUA applies to Terumo BCT Inc.’s Spectra Optia Apheresis System and Marker Therapeutics AG’s Depuro D2000 Adsorption Cartridge
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…